<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05101551</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 59562</org_study_id>
    <secondary_id>PEDSHEMAML0008</secondary_id>
    <nct_id>NCT05101551</nct_id>
  </id_info>
  <brief_title>Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination With Conventional Chemotherapy</brief_title>
  <acronym>PARPAML</acronym>
  <official_title>A Phase I Protocol for Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination With Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open label, multicenter, dose finding study with dose expansion intended&#xD;
      to evaluate the safety and tolerability of talazoparib in combination with conventional&#xD;
      chemotherapy. Preliminary estimates of efficacy will be obtain through a dose expansion&#xD;
      cohort receiving the maximum tolerated dose from the dose escalation phase of the study.&#xD;
&#xD;
      This study aims to determine the safety of talazoparib in combination with conventional&#xD;
      chemotherapy and to establish the maximum tolerated dose of all 3 drugs when given in&#xD;
      combination. A preliminary estimate of efficacy through a dose expansion phase is a secondary&#xD;
      aim.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT).</measure>
    <time_frame>28 days28 days after starting therapy (ie, single course of therapy).</time_frame>
    <description>Patient safety is assessed as dose limiting toxicity (DLT). The outcome is the number of DLT events. A DLT event is defined as a Grade 3, 4, or 5 event, with the exception of following Grade 3 4 events.&#xD;
Infection and/or fever&#xD;
Elevation in liver enzymes&#xD;
Changes in blood electrolyte levels for &gt; 24 hours.&#xD;
Changes in blood sugar for &gt; 24 hours.&#xD;
Fatigue and/or nausea (Grade 3 only).&#xD;
Vomiting and/or diarrhea (Grade 3 only) ≤ 7 days&#xD;
Hypotension associated with sepsis or infusion reaction&#xD;
Mucositis (Grade 3 only) ≤ 14 days&#xD;
Anorexia (Grade 3 only)&#xD;
Hypertension (Grade 3 only)&#xD;
Enterocolitis, typhlitis, or colitis (Grade 3 only)&#xD;
Gastric hemorrhage, gastric ulcer, gastritis, and/or upper GI bleed (Grade 3 only)&#xD;
Glucose intolerance (Grade 3 only)&#xD;
Leukoencephalopathy and/or seizures (Grade 3 only)&#xD;
Any Grade 3 event secondary to an infectious process or thrombocytopenia&#xD;
Other Grade 3 events resolving ≤ 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response (OR)</measure>
    <time_frame>28 days.</time_frame>
    <description>Objective response (OR) is a collective term representing all participants that achieve a complete response or partial response, and will be assessed for all participants treated at the maximum tolerated dose, including the Dose Expansion cohort. Response will be defined as below:&#xD;
Complete remission (CR) or complete remission without hematologic recovery (CRi): Bone marrow MRD &lt;0.1% by flow cytometry&#xD;
Complete response (CRM) or without hematologic recovery (CRMi): Bone marrow MRD 0.1 to 5% by flow cytometry&#xD;
Partial response (PR): A decrease of at least 50% in the percentage of morphologic blasts and 5% to 25% blasts by flow cytometry&#xD;
No response (NR): No change in clinical or laboratory status&#xD;
Progressive Disease (PD): Deterioration of initial disease status The outcome will be reported as the number of participants that achieve OR, ie, a CR, CRi, CRM, CRMi, or PR. The outcome is a number without dispersioni.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Talazoparib with topotecan and gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Talazoparib will be administered orally on Days 1 to 5 concurrently with topotecan and a single dose of gemcitabine on Day 1 of each 28 day cycle for 1 cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talazoparib</intervention_name>
    <description>Talazoparib will be administered in escalating doses based on current dose level.&#xD;
Dose Level 1: 400 µg/m2/dose once daily&#xD;
Dose Level 2: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5&#xD;
Dose Level 3: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5&#xD;
Dose Level 4: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5&#xD;
Dose Level 5: 600 ug/m2/dose BID on Day 1, then daily on Days 2 to 5 and 15 19</description>
    <arm_group_label>Talazoparib with topotecan and gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>Administered IV route on Days 1 to 5. Recommended dose based on this study is 4 mg/m2/dose.</description>
    <arm_group_label>Talazoparib with topotecan and gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Single dose (IV) of gemcitabine on Day 1 of each 28 day cycle for 1 cycle.</description>
    <arm_group_label>Talazoparib with topotecan and gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. AML or acute leukemia of ambiguous lineage (acute undifferentiated leukemia or&#xD;
             mixed phenotype acute leukemia) and have (a) refractory leukemia, defined as&#xD;
             persistent leukemia after at least two courses of induction chemotherapy, OR&#xD;
             (b)relapsed leukemia, defined as ≥ 1% blasts in the bone marrow OR rising MRD by flow&#xD;
             cytometry on two or more serial samples.&#xD;
&#xD;
        If an adequate bone marrow sample cannot be obtained, subjects may be enrolled if there is&#xD;
        unequivocal evidence of leukemia with ≥ 5% blasts in the peripheral blood.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Uncontrolled infection. Infections controlled on concurrent anti microbial agents&#xD;
             are acceptable, and anti microbial prophylaxis per institutional guidelines are&#xD;
             acceptable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer L Kamens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Universiy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Cardone</last_name>
    <phone>650-723-7006</phone>
    <email>Sarahcardone@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sarah Cardone</last_name>
      <email>Sarahcardone@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Kamens</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tanja Gruber</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Norman Lacayo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PARP Inhibitor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Talazoparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

